About Us

Our History

2000
WuXi PharmaTech was founded to support innovators in discovering, developing and commercializing new medicines and healthcare products for patients
2001
Launched synthetic chemistry services
2003
Began manufacturing process development services
2004
Initiated manufacturing services for research and development
2005
Started bio-analytical services
2007
Began offering toxicology and formulation services
Listed on the New York Stock Exchange
2008
Acquired AppTec Laboratory Services, after which the company was renamed WuXi AppTec
2011
Acquired Medkey, expanding to clinical development and registration services
First annual WuXi Global Forum held in San Francisco alongside the J.P. Morgan Healthcare Conference
2014
Acquired XenoBiotic Laboratories, adding to the company’s research capabilities
2015
Expanded medical device testing services
Delisted from the New York Stock Exchange
2016
Acquired CRELUX, enhancing WuXi AppTec's structure-based drug discovery capabilities
2017
Acquired HD Biosciences, strengthening biology R&D capacity and capability
Acquired ResearchPoint Global, expanding U.S. clinical research capabilities
2018
Listed on Shanghai Exchange (603259.SH)
Listed on Hong Kong Exchange (2359.HK)
2019
Acquired Pharmapace, to enhance biometrics services for clinical development
2021
Purchased Bristol Myers Squibb manufacturing facility in Couvet, Switzerland
Acquired OXGENE to further strengthen cell and gene therapy service offerings for global customers